Hifuture Technology(SZ:002168)2026-01-30 10:30Financial Performance - The company expects a net profit of between -10,000 and -6,000 million CNY for the fiscal year 2025, compared to -14,952.20 million CNY in the same period last year [4]. - Total revenue is projected to be between 36,000 and 45,000 million CNY, showing significant growth from 19,723.59 million CNY year-on-year [4]. - The company's equity attributable to shareholders is projected to improve to between 1,800 and 2,700 million CNY, a significant recovery from -5,482.35 million CNY last year [4]. Cost Management - The company has successfully reduced management expenses, contributing to improved profitability despite ongoing losses [7]. Acquisitions and Investments - The acquisition of 51% stake in Chongqing Ruien Pharmaceutical Co., Ltd. has positively impacted the company's performance in the biopharmaceutical sector [7]. - Fair value losses on investment properties are anticipated to be around 18 million CNY due to underperformance of investment assets [7]. Debt and Assets - The company received a debt waiver of 130 million CNY from creditors, which has positively influenced the net assets attributable to shareholders [7]. - Asset impairment losses are expected to be approximately 31 million CNY due to the recognition of certain assets showing signs of impairment [7]. Risks and Future Outlook - The company warns of potential delisting risks due to negative net assets and revenue below 300 million CNY in the previous fiscal year [8]. - The final audited financial results for 2025 will be disclosed in the annual report, which may differ from the preliminary estimates provided [8].